SAB4200122

Monoclonal Anti-OSTF1 antibody produced in mouse

~1.5 mg/mL, clone OSTF1, affinity isolated antibody

• Synonym(s): Anti-OSF, Anti-Osteoclast-stimulating factor 1, Anti-SH3P2
• UNSPSC Code: 12352203
• NACRES: NA.41

Properties

• biological source: mouse
• conjugate: unconjugated
• antibody form: affinity isolated antibody
• antibody product type: primary antibodies
• clone: OSTF1, monoclonal
• form: buffered aqueous solution
• mol wt: antigen ~28 kDa
• species reactivity: bovine, canine, human, monkey, mouse, rat
• packaging: antibody small pack of 25 μL
• concentration: ~1.5 mg/mL
• technique(s): western blot: 2-4 μg/mL using A431, Hepa1-6, NRK or PC12 cell extracts
• UniProt accession no.: Q92882
• shipped in: dry ice
• storage temp.: −20°C
• target post-translational modification: unmodified
• Gene Information: human ... OSTF1(26578)

Description

General description

Monoclonal Anti-OSTF1 (mouse IgG1 isotype) is derived from the hybridoma OSTF103 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a synthetic peptide. Osteoclast-stimulating factor (OSF or OSTF1) is an intracellular protein, highly expressed in osteoclasts. This protein is composed of a Src homology 3 (SH3) domain followed by three ankyrin repeats. OSTF1 also contains proline and aspartate largely at the N-terminal and C-terminal regions respectively. The gene OSTF1 is mapped to human chromosome 9q21.13.

Specificity

Monoclonal Anti-OSTF1 recognizes human, monkey, dog, bovine, rat, and mouse OSTF1.

Application

Monoclonal Anti-OSTF1 antibody produced in mouse is suitable for immunoblotting.

Biochem/physiol Actions

Osteoclast-stimulating factor (OSF or OSTF1) indirectly enhances osteoclast (OCL) formation and bone resorption through a cellular signal transduction cascade. This may be possible through its interaction with c-Src or other c-Src-related proteins. The domain structure of OSTF1 suggests that it potentially participates in protein-protein interactions. The Src homology 3 (SH3) domain is known to associate with survival motor neuron (SMN), a spinal muscular atrophy disease determining gene product. This interaction results in the stimulation of OCL formation. Inferring that OSF SH3-SMN interaction may be critical in congenital bone fractures associated with type I spinal muscular atrophy disease. Hindrance in the OSF-SH3 domain interaction with its protein partners might decrease bone resorption by OCL. This could prevent the bone loss associated with many bone diseases, such as osteoporosis, periodontal disease, estrogen deficiency, inflammatory bone loss, hyperparathyroidism, bone malignancy and Paget′s disease.

Physical form

Solution in 0.01M phosphate buffered saline pH 7.4, containing 15 mM sodium azide.

Storage and Stability

Store at –20 °C. For continuous use, the product may be stored at 2–8 °C for up to one month. For extended storage, freeze at –20 °C in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Safety Information

• Storage Class: 10 - Combustible liquids
• flash_point_f: Not applicable
• flash_point_c: Not applicable